Glenmark Pharmaceuticals Limited (GLENMARK) — Announcement | 11 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Glenmark settles U.S. antitrust case with Humana for $15.28 million

Glenmark Pharmaceuticals disclosed a settlement agreement with Humana to resolve U.S. antitrust litigation concerning generic drug pricing, agreeing to pay $15.28 million without admitting liability, with the company stating the settlement will not significantly affect its financial position.

📄 View Original Announcement (PDF)

About Glenmark Pharmaceuticals Limited (GLENMARK)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹68,205.11 Cr P/E: 37.9 ROE: 20.3% ROCE: 24.8% Div Yield: 0.10%

View full GLENMARK stock details →

📡 Get AI alerts when GLENMARK files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track GLENMARK — Free

📊 More GLENMARK filings

See all GLENMARK filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when GLENMARK files new disclosures

Track GLENMARK filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GLENMARK — Free

Free account · 2 AI queries/day